Looking at options history for Vertex Pharmaceuticals (NASDAQ: VRTX) we detected 10 trades. If we consider the specifics of ...

ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” third-quarter ...

Fintel reports that on October 10, 2025, Morgan Stanley maintained coverage of Vertex Pharmaceuticals (NasdaqGS:VRTX) with a Equal-Weight recommendation. Analyst Price Forecast Suggests 18.17% Upside ...

If you're holding shares of Vertex Pharmaceuticals or thinking about adding some to your portfolio, you're not alone in ...

Vertex faces pressure from potential U.S. drug pricing reforms and tariffs. Click here to find out why VRTX stock is a Hold.

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

Vertex Pharmaceuticals (VRTX) shares saw mild movement today, with the stock ticking slightly higher over the past week.

Ratings for Vertex Pharmaceuticals (NASDAQ: VRTX) were provided by 15 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.

Vertex Pharmaceuticals Inc. closed 22.25% short of its 52-week high of $519.88, which the company reached on November 8th.

Vertex Pharmaceuticals’ CRISPR-based therapy made history as the first drug of its type, transforming care options for sickle ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.